RxDoctor Payments Data

John McGill, MD

Urology · Newport News, VANPI 1982847703

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,080 of the $29,733 with a category attached, or 64.2%. Merck accounts for 86.3% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $26,250, more than ten times the $493 reported in 2019. Among urology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,733in general payments, 2019–2025

Across 127 payments — averaging $234.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$26K
  • Boston Scientific$2K
  • Astellas Pharma US Inc$550
  • Intuitive Surgical$455
  • Procept Biorobotics Corporation$297
  • AbbVie$216
  • plus $721 from 15 others

What the payments were for

  • Speaking & faculty fees$19,08064%
  • Travel & lodging$7,73926%
  • Food & beverage$2,91410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,733 in reported general payments places this provider in the 90th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$113,309
Medicare patients
255
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron30$20,613
GemtesaVibegron23$10,825
Tamsulosin Hcl247$2,375
Testosterone Cypionate52$2,300
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen259$913
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav139$849
Finasteride83$748
Oxybutynin Chloride ErOxybutynin Chloride50$645
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim104$275
Ciprofloxacin Hcl24$232
Alfuzosin Hcl ErAlfuzosin Hcl14$210
Oxybutynin Chloride12$137
Tramadol Hcl31$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$550$20,61330 claims
Sumitomo Pharma America, Inc.Gemtesa$143$10,82523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 urology providers in Virginia.

Other urology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →